Showing 4681-4690 of 5957 results for "".
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I
- Complexity Gaming Kicks Off Year-Long Partnership With Alconhttps://modernod.com/news/complexity-gaming-kicks-off-year-long-partnership-with-alcon/2479475/Esports company Complexity Gaming announced a partnership with Alcon. The partnership will designate Alcon’s signature brand of lubricant eye drops, Systane, as the first official eye care partner of Complexity Gaming. Now more than ever, dry eye symptoms are affecting people due to increa
- American Academy of Optometry Foundation Announces Award Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/Jonathan D. Lam, MD, OD, was this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Lam is a primary care/ocular disease resident at the Chinle Comprehensive Health Care Facility in Chinle, Arizona. Douglas W. Hopkins, OD, FAAO, was a leader within the Primary Care Section
- Market Scope: Phaco and FLACS Upgrades to Drive Expansion in Cataract Equipment Markethttps://modernod.com/news/market-scope-phaco-and-flacs-upgrades-to-drive-expansion-in-cataract-equipment-market/2479462/A number of market leaders in phaco and femtosecond cataract technology will launch upgraded platforms over the next year, which is expected to increase market penetration for both types of systems and stimulate the replacement of older models. Johnson & Johnson Vision has introduced i
- AAO: Proof of COVID-19 Vaccination Required for All Registrants Attending Annual Meeting in New Orleanshttps://modernod.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/The American Academy of Ophthalmology’s board of trustees has decided that proof of COVID-19 vaccination will be required for all registrants attending the Academy’s annual meeting in New Orleans. Every AAO 2021 attendee, all Academy staff, exhibitors, and guests will be required to
- US Prepares for Wide Rollout of COVID-19 Boosters Next Monthhttps://modernod.com/news/us-prepares-for-wide-rollout-of-covid-19-boosters-next-month/2479458/US officials announced that health agencies in the country are preparing to widely distribute third doses of mRNA COVID-19 vaccines beginning the week of September 20, citing new data that point to waning protection over time. The move was unveiled in a statement signed by health leaders includin
- Eyeque Announces Series C Closing With More Than $57 Million in Capital Raisedhttps://modernod.com/news/eyeque-announces-series-c-closing-with-more-than-57-million-in-capital-raised/2479459/EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMDhttps://modernod.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing a
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- Retina Consultants of America Expands Into North Carolinahttps://modernod.com/news/retina-consultants-of-america-expands-into-north-carolina/2479446/Physician management services organization Retina Consultants of America (RCA) had added North Carolina Retina Associates (NC Retina Associates) to its national consortium. Terms of the deal were not disclosed. The addition of NC Retina Associates marks RCA’s first entry into the No